Atracurium

CAS No:
64228-79-1 Category:
  • #LGM Pharma is a Atracurium CAS# 64228-79-1 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 64228-79-1
  • AHFC code: 12:20.0
  • Synonyms: Atracurium, BRN 1523633, UNII-2GQ1IRY63P
  • ATC Code: M03AC04
  • Chemical Formula: C53-H72-N2-O12
  • Molecular Weight: 929.154
  • Assay/Purity: Typically NLT 98%
  • DrugBank:
  • SMILES: c12c(cc(OC)c(c1)OC)CC[N,,+]([C,,H]2Cc1cc(c(OC)cc1)OC)(CCC(OCCCCCOC(CC[N,,+]1([C,,H](c2c(cc(OC)c(c2)OC)CC1)Cc1cc(c(OC)cc1)OC)C)=O)=O)C
  • InChl:
  • PubChem:
  • IUPAC:

Additional Details

Indication:
For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Pharmacodynamics:
Atracurium is a nondepolarizing skeletal muscle relaxant. Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by Atracurium is approximately one third to one half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of Atracurium. Repeated administration of maintenance doses of Atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.
Mode of Action:
Atracurium antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.
Metabolism:
Toxicity:
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos